Mahana Therapeutics has formed a significant partnership with Bayer's Consumer Health division to commercialise digital therapeutics, leveraging Mahana's expertise in this field with Bayer's interest in offering digital solutions for personalised health.
This collaboration aims to provide people with tools to manage their health through digital means. Mahana, a prominent provider of prescription digital therapeutics, will work with Bayer to make their innovative treatments more accessible worldwide.
Bayer's recent focus on digitally enabled precision health products aligns with this venture, marking one of the first major investments by a global life sciences company in the digital therapeutics market.
This partnership reflects the growing recognition of digital therapeutics as a crucial aspect of future healthcare.
Click here to read the original news story.